Gilead Sciences (GILD) PT Raised to $111 at Piper Jaffray Post Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Gilead Sciences (GILD) PT Lifted to $165 at BMO Capital on Strong Q2
July 24, 2014 6:40 AM EDTBMO Capital analyst Jim Birchenough, M.D.boosted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $165.00 (from $120.00) following Q2 results.
Birchenough comments, "With SOVALDI continuing to set sales records on a background of incomplete insurance coverage in the U.S.,... More
Gilead Sciences, Inc. (GILD) Tops Q2 EPS by 63c; Boosts FY14 Revenue Outlook
July 23, 2014 4:07 PM EDTGilead Sciences, Inc. (NASDAQ: GILD) reported Q2 EPS of $2.36, $0.63 better than the analyst estimate of $1.73. Revenue for the quarter came in at $6.53 billion versus the consensus estimate of $5.68 billion.
During the second quarter, Gilead continued to make significant progress led by strong Sovaldi sales. Since Decembers launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical communitys recognition of the benefits of this product, said John C. Martin, PhD, Gileads Chairman and Chief Executive Officer. We look forward to making Sovaldi available in additional... More
